| ADR | Adverse Drug Reactions |
| ALT | Alternative Lengthening of Telomeres |
| ATM | Ataxia–Telangiectasia Mutated |
| ATR | Ataxia–Telangiectasia And Rad3-Related Kinases: |
| ATRX | Alpha Thalassemia/Mental Retardation Syndrome X-Linked |
| BER | Base Excision Repair |
| BIR | Break-Induced Replication |
| BLM | Bloom Syndrome Protein |
| BRCA | Adverse Drug Reactions |
| CAF | Cancer-Associated Fibroblasts |
| CST complex | Ctc1–Stn1–Ten1 Complex |
| DAXX | Death Domain-Associated Protein |
| DDR | Dna Damage Response |
| DNA-PK | Dna-Dependent Protein Kinase |
| DR | Direct Repair |
| DSB | Double-Strand Break |
| EBV | Epstein-Barr Virus |
| ecDNA | Extrachromosomal Dna |
| EEC | Endometrioid Endometrial Cancer |
| EGCG | Epigallocatechin Gallate |
| FVYL | Conserved Hydrophobic Pocket (Phenylalanine/Valine/Tyrosine/Leucine) |
| GnRHR | Gonadotropin-Releasing Hormone Receptor |
| HGSOC | High-Grade Serous Ovarian Cancer |
| HL | Hodgkin Lymphoma |
| HR | Homologous Recombination |
| hTERT | Human Telomerase Reverse Transcriptase |
| hTR | Human Telomerase |
| MMEJ | Microhomology-Mediated End-Joining |
| MMR | Mismatch Repair |
| MRN | Mre11–Rad50–Nbs1 Protein Complex |
| NER | Nucleotide Excision Repair |
| NHEJ | Non-Homologous End Joining |
| NSCLC | Non-Small Cell Lung Cancer |
| OvC | Ovarian Cancer |
| POT1 | Protection of Telomeres 1 |
| RAP1 | Repressor/Activator Protein 1 |
| RP2D | Recommended Phase 2 Dose |
| RPA | Replication Protein A |
| SSA | Single-Strand Annealing |
| TERC | Human Telomerase Rna |
| TERT | Telomerase Reverse Transcriptase |
| TIL | Tumor-Infiltrating Lymphocytes |
| TIN2 | Trf-Interacting Nuclear Protein 2 |
| TL | Telomere Length |
| TPP1 | Tripeptidyl-Peptidase 1 |
| TRF1 | Telomeric Repeat-Binding Factor 1 |
| TRF2 | Telomeric Repeat-Binding Factor 2 |